Compare Amphastar Pharmaceuticals Inc (AMPH) vs Dropbox Inc (DBX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Dropbox Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Dropbox Inc trades at $33.64 (market cap $7.52B). The key difference: Dropbox Inc is far larger — about 8.7× Amphastar Pharmaceuticals Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | DBX | |
|---|---|---|
Market Cap | $863.95M | $7.52B |
Sector | Health | Technology |
52-Week High | $30.81 | $35.00 |
52-Week Low | $16.87 | $22.06 |
Enterprise Value | $1.26B | $10.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Dropbox (DBX) trades at $34.81, up 0.78% today, with a bullish technical signal and consistent earnings beats. The company reported Q2 2026 EPS of $0.75, exceeding estimates, and raised its full-year outlook. Revenue remains stable at $2.5B, with strong gross margins of 79.72%. However, negative shareholder equity and high debt levels pose financial risks.
The outlook is mixed: strong profitability and AI-driven growth support upside, but elevated leverage and competitive pressures warrant caution. Analyst sentiment is divided, with 37.5% recommending Buy. Key risks include execution challenges and market volatility. The stock's trajectory hinges on sustaining core business momentum amid macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
